Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2022 | Therapeutic potential of omega-3 supplementation in slowing cognitive decline for APOE4 carriers

The brains of people with APOE4 dementia tend to show higher levels of lipid inflammation, caused by lipid mediators of inflammation such as prostaglandins. Hussein Yassine, MD, Keck School of Medicine, University of Southern California, Los Angeles, CA, discusses how omega-3 supplementation given before the onset of dementia could help to decrease neuroinflammation and by extension decrease cognitive decline, in APOE4 carriers. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.